rifampin
rifampin: 16 clinical trials tracked.
rifampin evidence translation
What we can confirm
16 tracked trials
What it means
What to watch
Prepared research question
What is verified about rifampin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 5 study sponsors
Clinical Trial Registry Records (16)showing 10 most recent
An Open-label, Phase 1 Study to Characterize the Effects of Rifampin on the Pharmacokinetics of MK-8527 in Adult Participants With Latent Tuberculosis Infection
Primary endpoint: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of MK-8527
A Phase 1, Open-label, Randomized, Pharmacokinetic Study to Assess the Drug Interactions and Food Effect of Navlimetostat (BMS-986504) in Healthy Female Participants
Primary endpoint: Maximum observed concentration (Cmax) of Navlimetostat
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding
Primary endpoint: Proportion of participants with an unfavourable TB outcome
An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of INCB161734
Shortened Regimen for Drug-susceptible TB in Children
Primary endpoint: TB disease-free survival at 48-weeks
Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition
Primary endpoint: Death or first hospitalisation or failed nutritional recovery within 24 weeks post-randomisation
A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT)
Primary endpoint: Time to stable liquid culture conversion
A Phase 1, Open Label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib When Administered Alone and With Multiple Doses of Rifampin (CYP3A Inducer) or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects
Primary endpoint: Parts 1 and 2: Area Under the Concentration-time (AUC) of Brensocatib in Plasma
A Multicenter, Phase 2b/c, Open-label, Randomized, Dose-finding Trial to Evaluate the Safety and Efficacy of a 4 Month Regimen of OPC-167832 in Combination With Delamanid and Bedaquiline in Subjects With Drug-susceptible Pulmonary Tuberculosis in Comparison With Standard Treatment
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria
Multi-centric Prospective Cohort Study of TB Recurrence Free Cure Among Microbiologically Confirmed New Pulmonary Tuberculosis Patients Treated Under NTEP With the 4-month Moxifloxacin Containing Daily Regimen
Primary endpoint: TB recurrence free cure